Last reviewed · How we verify
non-nucleoside reverse transcriptase inhibitors
non-nucleoside reverse transcriptase inhibitors is a Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently FDA-approved.
Non-nucleoside reverse transcriptase inhibitors are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B, by inhibiting the activity of reverse transcriptase. Examples of non-nucleoside reverse transcriptase inhibitors include etravirine, which is used to treat HIV infection, and maraviroc, which is used to treat HIV-1 infection.
At a glance
| Generic name | non-nucleoside reverse transcriptase inhibitors |
|---|---|
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (PHASE2, PHASE3)
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
- Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (PHASE4)
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- non-nucleoside reverse transcriptase inhibitors CI brief — competitive landscape report
- non-nucleoside reverse transcriptase inhibitors updates RSS · CI watch RSS
- French National Agency for Research on AIDS and Viral Hepatitis portfolio CI
Frequently asked questions about non-nucleoside reverse transcriptase inhibitors
What is non-nucleoside reverse transcriptase inhibitors?
Who makes non-nucleoside reverse transcriptase inhibitors?
What development phase is non-nucleoside reverse transcriptase inhibitors in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing